IONS
IONIS PHARMACEUTICALS INC
Latest Form 4:Purchase$801KbyHayden Michael R (Director) · filed Jul 31, 2026
IONIS PHARMACEUTICALS INC (IONS) has 118 SEC Form 4 filings (338 transaction rows) in the rolling window, disclosed by 20 distinct insiders. Most recent filing: Jul 31, 2026.
The most active filer is EVP, Chief Business Officer Baroldi Joseph with 12 filings. Insiders have net sold $96.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Brett Monia
- Employees:1,069
- HQ:Carlsbad, CA, US
- IPO:1991-05-17
Insider Buying
$1.1M
reported purchases (SEC code P)
Insider Selling
$186.7M
reported sales (SEC code S)
Unique Insiders
20
in the rolling window
Market Cap
$10.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Hayden Michael RFirst filing | Director | Purchase | 15,000 | $801K | Jul 31 | SEC ↗ |
Hayden Michael RFirst filing | Director | Purchase | 5,000 | $258K | Jul 31 | SEC ↗ |
BENNETT C FRANKFirst in 4 months | EVP, Chief Scientific Officer | Sale | 20,536 | $1.7M | Jul 9 | SEC ↗ |
Diaz Allene M.First in 4 months | Director | Sale | 10,111 | $864K | Jul 9 | SEC ↗ |
| EVP, Chief Development Officer | Sale | 362 | $31K | Jul 9 | SEC ↗ | |
| Director | Sale | 11,518 | $910K | Jul 6 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 5,635 | $452K | Jun 30 | SEC ↗ | |
O'NEIL PATRICK R.First in 4 months | EVP CLO & General Counsel | Sale | 3,069 | $246K | Jun 30 | SEC ↗ |
Schneider EugeneFirst in 3 months | EVP, Chf Clinical Develop Ofcr | Sale | 26,000 | $2.1M | Jun 30 | SEC ↗ |
| Chief Executive Officer | Sale | 14,565 | $1.1M | Jun 26 | SEC ↗ | |
| Chief Executive Officer | Sale | 21,072 | $1.7M | Jun 26 | SEC ↗ | |
| Chief Executive Officer | Sale | 50,000 | $4.0M | Jun 26 | SEC ↗ | |
Swayze EricFirst in 4 months | EVP Research | Sale | 10,602 | $839K | Jun 26 | SEC ↗ |
Kordasiewicz Holly B.First in 5 months | EVP, Chief Development Officer | Sale | 60,846 | $4.5M | Jun 16 | SEC ↗ |
| Director | Sale | 8,000 | $588K | Jun 16 | SEC ↗ | |
BERTHELSEN SPENCER RFirst filing | Director | Sale | 8,000 | $605K | Jun 3 | SEC ↗ |
| Chief Executive Officer | Sale | 1,316 | $103K | May 15 | SEC ↗ | |
| Chief Executive Officer | Sale | 3,220 | $253K | May 15 | SEC ↗ | |
| Director | Sale | 77,289 | $5.8M | May 6 | SEC ↗ | |
| Director | Sale | 10,111 | $743K | May 5 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 1,626 | $117K | Apr 30 | SEC ↗ | |
| EVP, Chf GL Pdt Str Ofcr | Sale | 4,902 | $368K | Apr 17 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 5,619 | $419K | Apr 17 | SEC ↗ | |
| Director | Sale | 5,000 | $381K | Apr 17 | SEC ↗ | |
| EVP, Corp and Development Ops | Sale | 973 | $73K | Apr 17 | SEC ↗ | |
| Director | Sale | 22,321 | $1.7M | Apr 2 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 6,193 | $459K | Apr 2 | SEC ↗ | |
| EVP, Chf Clinical Develop Ofcr | Sale | 5,812 | $412K | Mar 23 | SEC ↗ | |
| EVP, Finance & CFO | Sale | 215,048 | $15.6M | Mar 18 | SEC ↗ | |
| EVP, Finance & CFO | Sale | 10,172 | $745K | Mar 18 | SEC ↗ | |
| Chief Executive Officer | Sale | 126,670 | $9.5M | Mar 11 | SEC ↗ | |
| Chief Executive Officer | Sale | 34,103 | $2.6M | Mar 11 | SEC ↗ | |
| EVP, Chf GL Pdt Str Ofcr | Sale | 37,277 | $2.8M | Mar 11 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 10,148 | $764K | Mar 11 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 20,106 | $1.6M | Mar 5 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 85,089 | $6.7M | Mar 5 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 6,220 | $496K | Mar 5 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 439 | $35K | Mar 5 | SEC ↗ | |
Diaz Allene M.First filing | Director | Sale | 54,878 | $4.4M | Mar 5 | SEC ↗ |
KLEIN JOSEPH IIIFirst in 3 months | Director | Sale | 21,332 | $1.7M | Mar 5 | SEC ↗ |
LOSCALZO JOSEPHFirst in 4 months | Director | Sale | 832 | $67K | Mar 5 | SEC ↗ |
LOSCALZO JOSEPHFirst in 4 months | Director | Sale | 200 | $16K | Mar 5 | SEC ↗ |
| EVP Research | Sale | 15,642 | $1.3M | Feb 13 | SEC ↗ | |
| Director | Sale | 5,000 | $414K | Feb 13 | SEC ↗ | |
| Chief Executive Officer | Sale | 29,430 | $2.5M | Feb 10 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 85,089 | $7.1M | Feb 4 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 5,885 | $488K | Feb 2 | SEC ↗ | |
| EVP Research | Sale | 6,179 | $512K | Feb 2 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 5,296 | $439K | Feb 2 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 6,179 | $516K | Feb 2 | SEC ↗ | |
| EVP, Corp and Development Ops | Sale | 6,179 | $513K | Feb 2 | SEC ↗ | |
| EVP, Chf Clinical Develop Ofcr | Sale | 6,179 | $516K | Feb 2 | SEC ↗ | |
| EVP, Finance & CFO | Sale | 6,988 | $582K | Feb 2 | SEC ↗ | |
| Chief Executive Officer | Sale | 62,970 | $5.2M | Feb 2 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 3,977 | $323K | Jan 23 | SEC ↗ | |
Baroldi JosephFirst in 3 months | EVP, Chief Business Officer | Sale | 8,056 | $610K | Jan 20 | SEC ↗ |
HOUGEN ELIZABETH LFirst in 4 months | EVP, Finance & CFO | Sale | 12,922 | $972K | Jan 20 | SEC ↗ |
Schneider EugeneFirst in 5 months | EVP, Chf Clinical Develop Ofcr | Sale | 9,302 | $703K | Jan 20 | SEC ↗ |
Kordasiewicz Holly B.First filing | EVP, Chief Development Officer | Sale | 4,141 | $313K | Jan 20 | SEC ↗ |
Monia Brett PFirst in 3 months | Chief Executive Officer | Sale | 44,034 | $3.3M | Jan 20 | SEC ↗ |
Jenne KyleFirst filing | EVP, Chf GL Pdt Str Ofcr | Sale | 1,823 | $138K | Jan 20 | SEC ↗ |
| EVP, Chief Human Resources Ofc | Sale | 8,353 | $634K | Jan 20 | SEC ↗ | |
BENNETT C FRANKFirst in 4 months | EVP, Chief Scientific Officer | Sale | 8,977 | $675K | Jan 20 | SEC ↗ |
| EVP, Corp and Development Ops | Sale | 8,480 | $637K | Jan 20 | SEC ↗ | |
O'NEIL PATRICK R.First in 3 months | EVP CLO & General Counsel | Sale | 9,191 | $697K | Jan 20 | SEC ↗ |
| EVP Research | Sale | 9,933 | $748K | Jan 20 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 44,199 | $3.8M | Jan 9 | SEC ↗ | |
| EVP Research | Sale | 23,463 | $1.9M | Jan 6 | SEC ↗ | |
| Director | Sale | 28,000 | $2.3M | Dec 3 | SEC ↗ | |
| Director | Sale | 4,000 | $320K | Nov 28 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 16,777 | $1.4M | Nov 28 | SEC ↗ | |
HERMAN JOAN EFirst filing | Director | Sale | 44,000 | $3.2M | Nov 20 | SEC ↗ |
| EVP, Chief Development Officer | Sale | 1,601 | $120K | Nov 7 | SEC ↗ | |
| EVP, Chief Development Officer | Sale | 33,038 | $2.5M | Nov 7 | SEC ↗ | |
| EVP, Chief Development Officer | Sale | 1,680 | $126K | Nov 7 | SEC ↗ | |
| EVP, Corp and Development Ops | Sale | 8,000 | $609K | Nov 7 | SEC ↗ | |
| Director | Sale | 16,800 | $1.2M | Nov 3 | SEC ↗ | |
| Director | Sale | 11,200 | $842K | Nov 3 | SEC ↗ | |
| EVP, Chief Development Officer | Sale | 89,249 | $6.7M | Nov 3 | SEC ↗ | |
| Director | Sale | 16,000 | $1.2M | Nov 3 | SEC ↗ | |
Birchler BrianFirst filing | EVP, Corp and Development Ops | Sale | 11,475 | $827K | Oct 16 | SEC ↗ |
Birchler BrianFirst filing | EVP, Corp and Development Ops | Sale | 12,425 | $897K | Oct 16 | SEC ↗ |
| EVP, Chief Human Resources Ofc | Sale | 6,000 | $438K | Oct 16 | SEC ↗ | |
| EVP, Chief Human Resources Ofc | Sale | 1,263 | $93K | Oct 16 | SEC ↗ | |
| Director | Sale | 5,000 | $359K | Oct 16 | SEC ↗ | |
| EVP Research | Sale | 53 | $4K | Oct 16 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 13,441 | $937K | Oct 8 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 1,625 | $113K | Oct 8 | SEC ↗ | |
| EVP Research | Sale | 6,849 | $473K | Oct 8 | SEC ↗ | |
| Chief Executive Officer | Sale | 437 | $30K | Oct 8 | SEC ↗ | |
| EVP Research | Sale | 14,142 | $935K | Oct 2 | SEC ↗ | |
| EVP Research | Sale | 12,972 | $859K | Oct 2 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 64,664 | $4.4M | Oct 2 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 15,000 | $1.0M | Oct 2 | SEC ↗ | |
| Director | Sale | 16,800 | $1.1M | Oct 2 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 10,473 | $676K | Oct 1 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 14,827 | $959K | Oct 1 | SEC ↗ | |
HOUGEN ELIZABETH LFirst filing | EVP, Finance & CFO | Sale | 49,800 | $3.2M | Oct 1 | SEC ↗ |
| EVP, Chief Development Officer | Sale | 57,900 | $3.8M | Oct 1 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 1,700 | $110K | Sep 16 | SEC ↗ | |
| EVP CLO & General Counsel | Sale | 21,000 | $1.4M | Sep 11 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 11,950 | $743K | Sep 11 | SEC ↗ | |
| EVP, Chief Scientific Officer | Sale | 6,000 | $358K | Sep 9 | SEC ↗ | |
| EVP, Chief Business Officer | Sale | 250 | $16K | Sep 9 | SEC ↗ | |
O'NEIL PATRICK R.First filing | EVP CLO & General Counsel | Sale | 13,050 | $711K | Sep 4 | SEC ↗ |
O'NEIL PATRICK R.First filing | EVP CLO & General Counsel | Sale | 76,850 | $4.7M | Sep 4 | SEC ↗ |
Monia Brett PFirst filing | Chief Executive Officer | Sale | 203,814 | $12.3M | Sep 4 | SEC ↗ |
BENNETT C FRANKFirst filing | EVP, Chief Scientific Officer | Sale | 5,000 | $246K | Sep 4 | SEC ↗ |
BENNETT C FRANKFirst filing | EVP, Chief Scientific Officer | Sale | 33,909 | $2.1M | Sep 4 | SEC ↗ |
Baroldi JosephFirst filing | EVP, Chief Business Officer | Sale | 32,800 | $1.9M | Sep 4 | SEC ↗ |
WENDER JOSEPH HFirst filing | Director | Sale | 16,800 | $939K | Sep 4 | SEC ↗ |
WENDER JOSEPH HFirst filing | Director | Sale | 11,200 | $674K | Sep 4 | SEC ↗ |
Schneider EugeneFirst filing | EVP, Chf Clinical Develop Ofcr | Sale | 19,658 | $1.2M | Sep 4 | SEC ↗ |
Devers Shannon L.First filing | EVP, Chief Human Resources Ofc | Sale | 3,162 | $193K | Sep 4 | SEC ↗ |
PARSHALL B LYNNEFirst filing | Director | Sale | 20,000 | $1.0M | Sep 4 | SEC ↗ |
Swayze EricFirst filing | EVP Research | Sale | 11,130 | $553K | Sep 4 | SEC ↗ |
KLEIN JOSEPH IIIFirst filing | Director | Sale | 28,000 | $1.7M | Sep 4 | SEC ↗ |
LOSCALZO JOSEPHFirst filing | Director | Sale | 16,000 | $962K | Sep 4 | SEC ↗ |
Geary Richard SFirst filing | EVP, Chief Development Officer | Sale | 10,000 | $504K | Sep 4 | SEC ↗ |
Related companies
IONIS PHARMACEUTICALS INC is in the Healthcare sector.